---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: OASIS-HAE"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: OASIS-HAE. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 23 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence/oasis-hae"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: OASIS-HAE

<a id="heading-3.1.4"></a>

## 3.1.4 OASIS-HAE

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Prophylaxis objective

> “prophylaxis to prevent attacks”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Registry study dates

> “Study Start (Actual) 2021-12-03”
> “Primary Completion (Actual) 2023-11-09”
> “Study Completion (Actual) 2023-11-09”

Source: [ClinicalTrials.gov NCT05139810](https://clinicaltrials.gov/study/NCT05139810)

<a id="topic-3.1.4.2-2"></a>

#### Registered study locations and countries

> “This study has 51 locations”

Source: [ClinicalTrials.gov NCT05139810](https://clinicaltrials.gov/study/NCT05139810)

| Field | Reported value |
| --- | --- |
| Country | “Belgium” |
| Country | “Bulgaria” |
| Country | “Canada” |
| Country | “Denmark” |
| Country | “France” |
| Country | “Germany” |
| Country | “Israel” |
| Country | “Italy” |
| Country | “Netherlands” |
| Country | “Poland” |
| Country | “Spain” |
| Country | “Turkey (Türkiye)” |
| Country | “United Kingdom” |
| Country | “United States” |

Source: [ClinicalTrials.gov NCT05139810](https://clinicaltrials.gov/study/NCT05139810)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Phase 3 design

> “double-blind, randomized”

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Age eligibility

> “12 years of age and older”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Dose, route, and dosing intervals

> “80 mg subcutaneously”
> “once every 4 or 8 weeks.”

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using HAE Attack Rate per Four Weeks as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Primary clinical endpoint: attack rate over the 24-week treatment period

> “HAE attacks per 4 weeks”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Planned enrollment

| Population | Participants |
| --- | --- |
| Planned total | “84” |

Source: [Ionis Pharmaceuticals protocol and statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf)

<a id="topic-3.1.4.7.1-2"></a>

##### Actual treated populations

| Population | Participants |
| --- | --- |
| Donidalorsen every four weeks | “45” |
| Donidalorsen every eight weeks | “23” |
| Placebo | “22” |

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Full analysis set

> “all randomized patients who received at least 1 dose of Study Drug”

Source: [Ionis Pharmaceuticals protocol and statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf)

<a id="topic-3.1.4.7.2-2"></a>

##### Primary count-data model

> “Poisson regression model and Pearson chi-square scaling of standard errors”

Source: [Ionis Pharmaceuticals protocol and statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf)

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

##### Treatment exposure

| Population | Participants |
| --- | --- |
| Treated | “90” |

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

##### Baseline demographics

| Characteristic | Reported value |
| --- | --- |
| Mean age, years (SD) | “37 (14)” |
| Female, n (%) | “48 (53)” |

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

##### Mean attack rate per four weeks: weeks 1–25 in the publication

| Treatment | Attack rate |
| --- | --- |
| Donidalorsen every four weeks | “0.44” |
| Donidalorsen every eight weeks | “1.02” |
| Placebo | “2.26” |

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

##### AE-QoL improvement relative to placebo at week 25: every-four-week regimen

> “18.6 points (95% CI, 9.5 to 27.7)”

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="topic-3.1.4.8.4-2"></a>

##### Exploratory and post hoc analysis status

> “All new analyses reported here are exploratory or post hoc, and resulting p‐values are nominal and not corrected for multiplicity.”

Source: [Riedl et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368753/)

<a id="topic-3.1.4.8.4-3"></a>

##### AE-QoL total score: clinically meaningful improvement at week 24

> “A greater proportion of the donidalorsen Q4W group achieved clinically meaningful improvement in AE‐QoL total score (≥ 6 points) vs. the placebo group (88.1% vs. 45.0%; odds ratio [OR], 12.2; 95% confidence interval [CI], 2.8 to 54.3; p < 0.001).”
> “Most Q8W patients (71.4%) also achieved the MCID, but while numerically larger, the difference between the donidalorsen Q8W and placebo groups was not statistically significant (OR, 3.5; 95% CI, 0.8 to 14.3; p = 0.087).”

Source: [Riedl et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368753/)

<a id="topic-3.1.4.8.4-4"></a>

##### AE-QoL domain scores from baseline to week 24

> “Patients reported decreases (improvements) in mean functioning domain scores from 45.2 at baseline to 8.0 at week 24 in the donidalorsen Q4W group and 51.2 to 18.2 in the donidalorsen Q8W group, compared with a decrease from 46.6 to 33.3 in the placebo group”
> “Mean fears/shame domain scores improved from 53.2 to 22.3, 54.8 to 27.1, and 57.0 to 51.6 in the donidalorsen Q4W, donidalorsen Q8W, and placebo groups, respectively.”
> “In the nutrition domain, patients reported improvements in means from 32.7 to 11.0 (Q4W), 36.9 to 17.6 (Q8W), and 36.4 to 28.5 (placebo).”
> “No significant differences in the change in the fatigue/mood domain were observed between the donidalorsen and placebo groups, but scores improved from 41.9 to 28.5 (Q4W), 39.5 to 31.4 (Q8W), and 34.1 to 30.3 (placebo).”

Source: [Riedl et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368753/)

<a id="topic-3.1.4.8.4-5"></a>

##### Angioedema Control Test: change from baseline and disease control at week 24

> “Least‐squares mean (LSM) changes from baseline to week 24 in AECT total score were statistically significantly larger in both the Q4W (7.2 points; 95% CI, 5.9 to 8.4) and Q8W donidalorsen (5.2 points; 95% CI, 3.4 to 7.0) groups than in the placebo group (1.2 points; 95% CI, −0.7 to 3.0; Q4W vs. placebo p < 0.001; Q8W vs. placebo p = 0.003).”
> “As reported previously, at week 24, 91% of patients in the donidalorsen Q4W group reported well‐controlled disease vs. 41% of patients in the placebo group”
> “a significantly greater proportion of patients in the donidalorsen Q8W group (74%) reported well‐controlled disease at week 24 compared with the placebo group (OR vs. placebo, 4.1; 95% CI, 1.2 to 14.4; p = 0.028).”
> “51% and 48% of patients in the donidalorsen Q4W and Q8W groups, respectively”
> “reported complete disease control (AECT = 16; Table 1).”

Source: [Riedl et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368753/)

<a id="topic-3.1.4.8.4-6"></a>

##### Patient Global Impression of Severity at week 24

> “82% of donidalorsen Q4W patients reporting improvement, that is, less severe disease at week 24 compared with baseline”
> “the 44% reporting improvements in disease severity in the placebo group (OR, 6.2; 95% CI, 1.4 to 28.2; p = 0.018; Figure 3).”

Source: [Riedl et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368753/)

<a id="topic-3.1.4.8.4-7"></a>

##### Work productivity and activity impairment at week 24

> “Mean presenteeism, the percent loss of productivity while at work/school, improved from 25.6% at baseline to 4.0% at week 24 in the donidalorsen Q4W group compared with a decrease from 30.7% to 19.8% in the placebo group”
> “Overall work/school impairment decreased from 28.4% to 4.7% in the donidalorsen Q4W group vs. 35.2% to 22.7% in the placebo group.”
> “Patients reported improvements in the overall activity impairment domain from 35.4% to 10.5% in the donidalorsen Q4W group vs. 34.7% to 21.2% in the placebo group.”
> “Numerical improvements from baseline to week 24 were observed in all WPAI domains in the donidalorsen Q8W group, but these changes did not reach significance vs. placebo”

Source: [Riedl et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368753/)

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

##### Injection-site reactions

| Treatment | Participants, n (%) |
| --- | --- |
| Donidalorsen every four weeks, n=45 | “11 (24)” |
| Donidalorsen every eight weeks, n=23 | “1 (4)” |
| Placebo, n=22 | “1 (5)” |

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary

The trial treated 90 participants: 45 received donidalorsen every 4 weeks, 23 received donidalorsen every 8 weeks, and 22 received placebo. The randomized comparison does not describe outcomes beyond Week 25. The full analysis set comprised “all randomized patients who received at least 1 dose of Study Drug”, and attack counts were analyzed with a “Poisson regression model and Pearson chi-square scaling of standard errors”. The placebo group of 22 participants and the every-8-week group of 23 participants limit precision for between-group estimates and for uncommon adverse events; injection-site reactions occurred in 11 of 45 participants (24%) receiving every-4-week dosing. Donidalorsen was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, baseline attack rates, observation periods, and attack-rate definitions (attacks per 4 weeks in this trial) can affect the reported rates.

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/); [Ionis Pharmaceuticals protocol and statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf); [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
